The MD Magazine Hepatitis C condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
Genetic Investigation of Lymphotropism in Hepatitis C
Jan 19, 2017
Researchers address the controversial topic of B-cell infection by hepatitis C.
Phase 3 Trial Reveals High Hepatitis C Success Rate with Investigational Drug
Jan 18, 2017
Glecaprevir/pibrentasvir had a 99% SVR rate in a Japanese population.
VA Finds Success with Various Hepatitis C Regimens for Veterans
Jan 13, 2017
The US Department of Veteran Affairs is finding success with modern DAAs.
Interferon-Free 3D Treatment for Hepatitis C Works Fast
Jan 12, 2017
3D treatment helped patients to attain SVR in less than 12 weeks.
High Frequency of Tregs After Curing Hepatitis C Could Enhance Liver Cancer Risk
Jan 11, 2017
Even after eradicating hepatitis C with direct-acting antivirals, high frequency of Tregs could pose complications.
Court Orders Gilead to Pay Merck in Hepatitis C Drug Patent Lawsuit
Jan 10, 2017
Merck just got $2.54 billion richer with the ruling of a federal jury.
Officials Investigate HIV Transmission Risk Via Cosmetic Skin Treatment
Jan 09, 2017
A trip to the beauty salon could result in exposure to dangerous blood-borne viruses.
Multi-Genotype Hepatitis C Drug Application Lands in Front of the FDA
Dec 21, 2016
An investigational regimen of glecaprevir and pibrentasvir has proven to perform well in patients with hepatitis C genotypes 1 to 6 without cirrhosis.
Head-to-Head Comparison of Two Hepatitis C Regimens Reveals Superior
Dec 19, 2016
Elbasvir/grazoprevir (Zepatier) and sofosbuvir (Sovaldi) are used to treat hepatitis C around the world, but is one better than the other?
Tweets by @MDMagazine
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
Affiliated Websites >
American Journal of Managed Care
Cure Hepatitis C
Specialty Pharmacy Times
Rare Disease Report
MD Magazine Resources
Terms & Conditions
Copyright MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.